Get to know our clinical trials
Estudio de ASTX030 (cedazuridina en combinación con azacitidina) en los SMD, la LMMC o la LMA
THE PURPOSE OF THIS STUDY IS TO ANALYZE THE LEVELS OF THE EXPERIMENTAL DRUG ASTX030 IN YOUR BLOOD, EVALUATE THE SAFETY AND TOLERABILITY OF THE DRUGS, AND FIND OUT HOW PARTICIPANTS RESPOND TO THE DRUG.
Technical Summary
- MULTI-PHASE STUDY WITH A PROGRESSIVE DOSE INCREASE FOLLOWED BY AN OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY OF ORAL ASTX030 (COMBINED WITH CEDAZURIDINE AND AZACITIDINE) VERSUS SUBCUTANEOUS AZACITIDINE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS), CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML), OR ACUTE MYELOID LEUKEMIA (AML)
- Code EudraCT: 2024-515098-93
- Protocol number: ASTX030-01
- Promoter: Taiho Oncology, Inc.
- Molecule/Drug: ASTX030
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Who can participate?
Study of ASTX030 (cedazuridine in combination with azacitidine) in MDS, LMMC, or AML
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.